Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

Study Identifier
KD200010
CT.gov Identifier
NCT00679653
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Obesity or Weight Loss
  • Hypertension & Blood Pressure
    • Study Drug
  • sibutramine
  • verapamil/trandolapril
  • metoprolol/HCT
  • felodipine/ramipril
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    20 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Treated essential hypertension. - Obesity: BMI 27-35 kg/m2
    Exclusion Criteria:
    - Secondary hypertension. - Stage 3 hypertension. - Secondary obesity; BMI > 35kg/m2. - CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial fibrillation; myocarditis. - Kidney failure. - Liver failure. - Hyperthyroidism. - Unstable DM. - Carcinoma. - Severe chronic infectious disease. - Alcohol or drug abuse. - Pregnancy. - Epilepsy. - Psychosis or treatment with antidepressants or major tranquilizers

    Protocol Summary

    To study the effect of sibutramine treatment on weight reduction and blood pressure

    improvement in three groups with antihypertensive therapy whose blood pressure was not

    adequately controlled with antihypertensive combination treatment.

    Study Locations

    No locations found.